Multiple increased osteoclast functions in individuals with neurofibromatosis type 1

American Journal of Medical Genetics, Part A

Volumn 155, Issue 5, 2011, Pages 1050-1059

  Stevenson, David A ^a   Yan, Jincheng ^b,c   He, Yongzheng ^c   Li, Huijie ^b,c   Liu, Yaling ^b,c   Zhang, Qi ^b,c   Jing, Yongmin ^b,c   Guo, Zhiping ^b,c   Zhang, Wei ^b,c   Yang, Dalong ^b,c   Wu, Xiaohua ^c   Hanson, Heather ^a   Li, Xiaohong ^c   Staser, Karl ^c   Viskochil, David H ^a   Carey, John C ^a   Chen, Shi ^c   Miller, Lucy ^c   Roberson, Kent ^c   Moyer Mileur, Laurie ^a   Yu, Menggang ^c   Schwarz, Elisabeth L ^d   Pasquali, Marzia ^a   Yang, Feng Chun ^c   more..

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

Author keywords

Bone mineral density; Bone resorption; Neurofibromatosis type 1; Osteoporosis; Ras

Indexed keywords

COLONY STIMULATING FACTOR 1; F ACTIN; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; RHO GUANINE NUCLEOTIDE BINDING PROTEIN;

ADOLESCENT; ADULT; ARTICLE; BIOCHEMISTRY; BONE DEFECT; BONE DENSITY; BONE RADIOGRAPHY; CELL ADHESION; CELL CULTURE; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFANT; MAJOR CLINICAL STUDY; NEUROFIBROMATOSIS; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; PHENOTYPE; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN POLYMERIZATION; SCHOOL CHILD; STEM CELL;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ADULT; BLOTTING, WESTERN; CELL ADHESION; CELL PROLIFERATION; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; ENZYME ACTIVATION; GTP PHOSPHOHYDROLASES; HUMANS; INFANT; MICROSCOPY, FLUORESCENCE; MITOGEN-ACTIVATED PROTEIN KINASES; NEUROFIBROMATOSIS 1; OSTEOCLASTS;

EID: 79955007125     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.33965     Document Type: Article

References (43)

1. Ajuebor MN, Hogaboam CM, Kunkel SL, Proudfoot AE, Wallace JL. 2001. The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat. J Immunol 166:552-558.
2. Atit RP, Crowe MJ, Greenhalgh DG, Wenstrup RJ, Ratner N. 1999. The Nf1 tumor suppressor regulates mouse skin wound healing, fibroblast proliferation, and collagen deposited by fibroblasts. J Invest Dermatol 112:835-842.
3. Atit RP, Mitchell K, Nguyen L, Warshawsky D, Ratner N. 2000. The neurofibromatosis type 1 (Nf1) tumor suppressor is a modifier of carcinogen-induced pigmentation and papilloma formation in C57BL/6 mice. J Invest Dermatol 114:1093-1100.
4. Aubin JE. 1992. Osteoclast adhesion and resorption: the role of podosomes. J Bone Miner Res 7:365-368.
5. Bajenaru ML, Hernandez MR, Perry A, Zhu Y, Parada LF, Garbow JR, Gutmann DH. 2003. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res 63:8573-8577.
6. Boyle WJ, Simonet WS, Lacey DL. 2003. Osteoclast differentiation and activation. Nature 423:337-342.
7. Cichowski K, Jacks T. 2001. NF1 tumor suppressor gene function: narrowing the GAP. Cell 104:593-604.
8. Clementi M, Milani S, Mammi I, Boni S, Monciotti C, Tenconi R. 1999. Neurofibromatosis type 1 growth charts. Am J Med Genet 87:317-323.
9. Cormier JM, Cormier F, Mayade F, Fichelle JM. 1999. Arterial complications of neurofibromatosis. J Mal Vasc 24:281-286.
10. Dulai S, Briody J, Schindeler A, North KN, Cowell CT, Little DG. 2007. Decreased bone mineral density in neurofibromatosis type 1: results from a pediatric cohort. J Pediatr Orthop 27:472-475.
11. Fossali E, Signorini E, Intermite RC, Casalini E, Lovaria A, Maninetti MM, Rossi LN. 2000. Renovascular disease and hypertension in children with neurofibromatosis. Pediatr Nephrol 14:806-810.
12. Fujikawa Y, Sabokbar A, Neale SD, Itonaga I, Torisu T, Athanasou NA. 2001. The effect of macrophage-colony stimulating factor and other humoral factors (interleukin-1, -3, -6, and -11, tumor necrosis factor-alpha, and granulocyte macrophage-colony stimulating factor) on human osteoclast formation from circulating cells. Bone 28:261-267.
13. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, Rubenstein A, Viskochil D. 1997. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. J Am Med Assoc 278:51-57.
14. Heervä E, Alanne MH, Peltonen S, Kuorilehto T, Hentunen T, Väänänen K, Peltonen J. 2010. Osteoclasts in neurofibromatosis type 1 display enhanced resorption capacity, aberrant morphology, and resistance to serum deprivation. Bone 47:583-590.
15. Illes T, Halmai V, de Jonge T, Dubousset J. 2001. Decreased bone mineral density in neurofibromatosis-1 patients with spinal deformities. Osteoporos Int 12:823-827.
16. Ingram DA, Yang FC, Travers JB, Wenning MJ, Hiatt K, New S, Hood A, Shannon K, Williams DA, Clapp DW. 2000. Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J Exp Med 191:181-188.
17. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. 2005. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 102:8573-8578.
18. Kuorilehto T, Poyhonen M, Bloigu R, Heikkinen J, Vaananen K, Peltonen J. 2005. Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body. Osteoporos Int 16:928-936.
19. Kurien A, John PR, Milford DV. 1997. Hypertension secondary to progressive vascular neurofibromatosis. Arch Dis Child 76:454-455.
20. Lammert M, Kappler M, Mautner VF, Lammert K, Storkel S, Friedman JM, Atkins D. 2005. Decreased bone mineral density in patients with neurofibromatosis 1. Osteoporos Int 16:1161-1166.
21. Lane NE. 2006. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol 194:S3-S11.
22. McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, Novack D, Feng X, Ross FP, Hynes RO, Teitelbaum SL. 2000. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 105:433-440.
23. Ming W, Li S, Billadeau DD, Quilliam LA, Dinauer MC. 2007. The Rac effector p67phox regulates phagocyte NADPH oxidase by stimulating Vav1 guanine nucleotide exchange activity. Mol Cell Biol 27:312-323.
24. Roberts BJ, Thrall E, Muller JA, Bouxsein ML. 2010. Comparison of hip fracture risk prediction by femoral BMD and by the factor-of-risk for hip fracture derived from direct measurements of femoral strength. Bone 46:742-746.
25. Rutkowski JL, Wu K, Gutmann DH, Boyer PJ, Legius E. 2000. Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1. Hum Mol Genet 12:1059-1066.
26. Sanjay A, Houghton A, Neff L, DiDomenico E, Bardelay C, Antoine E, Levy J, Gailit J, Bowtell D, Horne WC, Baron R. 2001. Cbl associates with Pyk2 and Src to regulate Src kinase activity, alpha(v)beta(3) integrin-mediated signaling, cell adhesion, and osteoclast motility. J Cell Biol 152:181-195.
27. Schindeler A, Ramachandran M, Godfrey C, Morse A, McDonald M, Mikulec K, Little DG. 2008. Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild-type and Nf1 haploinsufficient mice. J Orthop Res 26:65-74.
28. Stevenson DA, Moyer-Mileur LJ, Murray M, Slater H, Sheng X, Carey JC, Dube B, Viskochil DH. 2007. Bone mineral density in children and adolescents with neurofibromatosis type 1. J Pediatr 150:83-88.
29. Stevenson DA, Schwarz EL, Viskochil DH, Moyer-Mileur LJ, Murray M, Firth SD, D'Astous JL, Carey JC, Pasquali M. 2008. Evidence of increased bone resorption in neurofibromatosis type 1 using urinary pyridinium crosslink analysis. Pediatr Res 63:697-701.
30. Stevenson DA, Zhou H, Ashrafi S, Messiaen LM, Carey JC, D'Astous JL, Santora SD, Viskochil DH. 2006. Double inactivation of NF1 in tibial pseudarthrosis. Am J Hum Genet 79:143-148.
31. Stumpf DA, Alksne JF, Annegers JF, Brown SS, Conneally PM, Housman D. 1988. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 45:575-578.
32. Sun Y, Buki KG, Ettala O, Vaaraniemi JP, Vaananen HK. 2005. Possible role of direct Rac1-Rab7 interaction in ruffled border formation of osteoclasts. J Biol Chem 280:32356-32361.
33. Takeshita S, Namba N, Zhao JJ, Jiang Y, Genant HK, Silva MJ, Brodt MD, Helgason CD, Kalesnikoff J, Rauh MJ, Humphries RK, Krystal G, Teitelbaum SL, Ross FP. 2002. SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts. Nat Med 8:943-949.
34. Tucker T, Schnabel C, Hartmann M, Friedrich RE, Frieling I, Kruse HP, Mautner VF, Friedman JM. 2009. Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1). J Med Genet 46:259-265.
35. Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM, Saulino AM, Fountain J, Brereton A, Nicholson J, Mitchell A, Brownstein B, Collins F. 1990. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249:181-186.
36. Wu X, Estwick SA, Chen S, Yu M, Ming W, Nebesio TD, Li Y, Yuan J, Kapur R, Ingram D, Yoder MC, Yang FC. 2006. Neurofibromin plays a critical role in modulating osteoblast differentiation of mesenchymal stem/progenitor cells. Hum Mol Genet 15:2837-2845.
37. Yan J, Chen S, Zhang Y, Li X, Li Y, Wu X, Yuan J, Robling AG, Kapur R, Chan RJ, Yang FC. 2008. Rac1 mediates the osteoclast gains-in-function induced by haploinsufficiency of Nf1. Hum Mol Genet 17:936-948.
38. Yang FC, Chen S, Robling AG, Yu X, Nebesio TD, Yan J, Morgan T, Li X, Yuan J, Hock J, Ingram DA, Clapp DW. 2006. Hyperactivation of p21 and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J Clin Invest 116:2880-2891.
39. Yang FC, Ingram DA, Chen S, Hingtgen CM, Ratner N, Monk KR, Clegg T, White H, Mead L, Wenning MJ, Williams DA, Kapur R, Atkinson SJ, Clapp DW. 2003. Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells. J Clin Invest 112:1851-1861.
40. Yang FC, Kapur R, King AJ, Tao W, Kim C, Borneo J, Breese R, Marshall M, Dinauer MC, Williams DA. 2000. Rac2 stimulates Akt activation affecting BAD/Bcl-XL expression while mediating survival and actin function in primary mast cells. Immunity 12:557-568.
41. Yilmaz K, Ozmen M, Bora Goksan S, Eskiyurt N. 2007. Bone mineral density in children with neurofibromatosis 1. Acta Paediatr 96:1220-1222.
42. Zhang YY, Vik TA, Ryder JW, Srour EF, Jacks T, Shannon K, Clapp DW. 1998. Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. J Exp Med 187:1893-1902.
43. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. 2002. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 296:920-922.